Loading
companiesCompany
ADC Therapeutics
ADC Therapeutics, based in Lausanne, developed Zynlonta (loncastuximab tesirine), an antibody-drug conjugate built on its pyrrolobenzodiazepine payload platform and approved in diffuse large B-cell lymphoma. It is now switching to exatecan-based payloads, so its future rests on changing platform while staying independent.
Also called: ADC Therapeutics S.A.ADC Therapeutics SA
Overview
ADC Therapeutics, based in Lausanne and listed as ADCT, developed Zynlonta, or loncastuximab tesirine, and the pyrrolobenzodiazepine payload platform behind it. Loncastuximab is approved in diffuse large B-cell lymphoma, the LOTIS-5 and LOTIS-7 trials test it in combinations, and the company is moving to exatecan-based next-generation ADCs. OnCo links it to diffuse large B-cell lymphoma and to the loncastuximab tesirine drug record. Whether a company built on one payload can change platform and stay independent is the open question. Loncastuximab tesirine has its own page.
Headquarters
Lausanne, CH
Scorecard
All companies#226of 1244 companies, score 23
- approved products +6
- targets +2
- modalities +2
- regions +4
- registry trials +9
1 approved, 0 in phase 3, 0 earlier, 1 targets, 22 registry studies. Formula on the scorecards page.
Type
Biotech · ADCT
Stage
Public
Website
ApprovedADC
Loncastuximab tesirine · Zynlonta
Loncastuximab tesirine (Zynlonta) is a CD19 ADC with a DNA-crosslinking payload for relapsed large B-cell lymphoma.
Similar pages
- TrialLOTIS-2
Shares Loncastuximab tesirine, Diffuse large B-cell lymphoma.
- TrialA Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
Shares Loncastuximab tesirine, Diffuse large B-cell lymphoma.
- TreatmentEmapalumab
Shares Sobi (Swedish Orphan Biovitrum), Diffuse large B-cell lymphoma.
- TreatmentPalifermin
Shares Sobi (Swedish Orphan Biovitrum), Diffuse large B-cell lymphoma.
- BiomarkerCD19 expression (CD19-positive)
Shares Loncastuximab tesirine, Diffuse large B-cell lymphoma.
- TermWhat the NHS in England funds for lymphoma, appraisal by appraisal
Shares Loncastuximab tesirine, Diffuse large B-cell lymphoma.